Oxolamine

Oxolamine is a cough suppressant available as a generic drug in many jurisdictions worldwide, though not approved in the United States. This medication possesses both antitussive and anti-inflammatory properties, making it effective in managing various respiratory conditions. This comprehensive review aims to provide detailed information about oxolamine, including its chemical characteristics, therapeutic applications, safety profile, and regulatory status.

Introduction

Oxolamine represents an important therapeutic option in the management of cough and respiratory tract inflammation in countries where it is approved. As a cough suppressant, it works by inhibiting the cough reflex while simultaneously reducing irritation of nerve receptors in the respiratory tract through its anti-inflammatory activity.

Despite its widespread use internationally, oxolamine lacks FDA approval in the United States, though it maintains prescription drug status in countries like New Zealand and has secured regulatory approval in Taiwan specifically for respiratory tract inflammation treatment. The medication plays a significant role in treating various respiratory conditions, including pharyngitis, tracheitis, bronchitis, bronchiectasis, and pertussis, offering symptomatic relief particularly for dry, bothersome coughs.

Chemical Structure

Oxolamine belongs to the chemical class of phenyloxadiazoles, which are polycyclic aromatic compounds containing a benzene ring linked to a 1,2,4-oxadiazole ring through a CC or CN bond. The molecular formula of oxolamine is C₁₄H₁₉N₃O with a molecular weight of 245.326 g·mol⁻¹. Its IUPAC name is 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-phenyl-.

The compound features a phenyl group attached to the oxadiazole ring, with a diethylaminoethyl chain extending from the fifth position of the oxadiazole structure. This unique chemical architecture contributes to its pharmacological properties and mechanism of action in the respiratory system.

Oxolamine-Based Medicines

Oxolamine is marketed under various brand names worldwide. Here are eight prominent oxolamine-based medicines available in different countries:

1. Perebron – Available in multiple countries in syrup and suppository forms
2. Aledron – Marketed by IQFA in Mexico
3. Antisot – Produced by Laboratorios Euromed Chile in Chile
4. Bronko – Manufactured by Lafar in Turkey
5. Broxol – Available from Galeno in Venezuela, including pediatric formulations
6. Numosol – Marketed by Pharmalab in Peru and available in different concentrations
7. Teratos – Produced by Neumobiotics in Chile
8. Toxolen – Available as a syrup formulation

These medications may contain oxolamine as a single active ingredient or in combination with other substances such as guaifenesin, bromhexine, or paracetamol, depending on the specific formulation and therapeutic intent.

Mechanism of Action

Oxolamine acts primarily as a cough suppressant by centrally inhibiting the cough reflex pathway. Research suggests its antitussive activity is more pronounced when responding to diffuse stimulation of the bronchial tree compared to electrical stimulation of the superior laryngeal nerve, indicating a predominantly peripheral mechanism of action.

This differentiates oxolamine from some other antitussive agents that work primarily through central pathways. Additionally, oxolamine exhibits significant anti-inflammatory activity, which contributes to reducing irritation of nerve receptors in the respiratory tract. This dual mechanism-suppressing the cough reflex while simultaneously addressing inflammation-enhances its therapeutic efficacy in respiratory conditions.

Beyond its primary antitussive and anti-inflammatory effects, oxolamine has been reported to possess analgesic, local anesthetic, and antispasmodic properties. These additional pharmacological activities may contribute to its overall therapeutic benefit in respiratory conditions, particularly those accompanied by pain or smooth muscle spasm.

Pharmacokinetics

The available literature provides limited detailed information regarding the pharmacokinetic profile of oxolamine. However, research has indicated that oxolamine may interact with certain metabolic enzymes, particularly in the liver. Studies in rats have demonstrated that oxolamine can inhibit CYP2B1/2 enzymes in male rats, which affects the metabolism of certain drugs such as warfarin.

This interaction appears to display gender specificity, with male rats showing different pharmacokinetic interactions compared to females when oxolamine is administered concurrently with warfarin.

The research suggests that the inhibition of these cytochrome P450 enzymes by oxolamine could be responsible for the observed increased area under the curve (AUC) when warfarin is co-administered with oxolamine. However, comprehensive human pharmacokinetic parameters including absorption, distribution, metabolism, and excretion details are not thoroughly documented in the available literature.

Therapeutic Uses

Oxolamine is employed in treating various respiratory conditions, as summarized in the table below:

The medication is particularly valuable for symptomatic relief of dry, uncomfortable, and persistent cough, where its dual antitussive and anti-inflammatory properties provide effective relief.

Dosage and Administration

Oxolamine is administered orally and is available in various formulations, with specific dosing guidelines based on age and formulation:

For adults, the typical recommended dosage is 10 ml of syrup every 4 hours. Some alternative dosing regimens suggest 2 ml of 5 ml concentration four times daily, which should be taken with an equal amount of water.

For pediatric patients, dosing is more carefully calibrated based on age: children between 4 months and 2 years should receive 7.5 mg/kg/day, typically administered as 2.5 ml three times daily. Children aged 2 to 10 years are generally prescribed 7.5 mg/kg/day or 5 ml three times daily. Another dosing guideline suggests a general approach of 15-25 mg per kilogram per day divided into four equal doses for children.

It’s important to note that for children, the duration of treatment should not exceed 5 days unless specifically indicated by a healthcare provider. This restriction helps minimize any potential risks associated with prolonged use in pediatric populations.

Side Effects

Oxolamine is generally well-tolerated, with research indicating low acute and chronic toxicities. However, as with any medication, adverse effects can occur. The most serious documented adverse event is visual hallucinations, which was reported in a pediatric patient following an overdose. This suggests that central nervous system effects are possible, particularly at higher-than-recommended doses.

The experimental results referenced in the literature indicate an absence of significant side effects when the medication is used as directed. However, the limited availability of comprehensive clinical trial data and post-marketing surveillance information restricts a complete assessment of all potential adverse effects.

Users should be vigilant for any unusual reactions and report them to healthcare providers immediately, especially in pediatric patients where monitoring should be more careful due to their heightened sensitivity to medications and different metabolic profiles compared to adults.

Drug Interactions

The most significant documented drug interaction for oxolamine is with warfarin, a commonly prescribed anticoagulant. Studies have shown that oxolamine can increase the anticoagulant effect of warfarin, potentially by inhibiting CYP2B1/2 enzymes involved in warfarin metabolism. This interaction appears to have gender-specific characteristics, with studies demonstrating that male rats show significantly greater area under the curve (AUC) for warfarin when co-administered with oxolamine, while female rats do not show the same effect.

The research suggests that this interaction occurs primarily through oxolamine’s inhibition of CYP2B1 in male rats, as warfarin is metabolized via several cytochrome P450 enzymes, including CYP1A1, 2B1, 2C6, 2C11, and 3A2. The clinical significance of this finding for human patients taking both medications requires careful consideration and potentially adjusted dosing or increased monitoring of international normalized ratio (INR) values.

Given these findings, patients taking warfarin or other medications metabolized by similar pathways should exercise caution when using oxolamine and consult with their healthcare providers about potential interactions.

Safety Considerations

Several safety considerations should be observed when using oxolamine. The primary contraindication is hypersensitivity to oxolamine citrate or any of the excipients in the formulation. Patients with known allergies to similar compounds should exercise caution and discuss alternatives with their healthcare providers.

For pediatric patients, particular attention should be paid to the recommended duration of treatment, which should not exceed 5 days unless specifically indicated by a healthcare provider. This limitation helps prevent potential adverse effects from prolonged use in children, whose developing systems may respond differently to medications compared to adults.

While oxolamine demonstrates low acute and chronic toxicity in experimental studies, the relative absence of extensive post-marketing surveillance data suggests that vigilance is warranted, particularly for novel or rare adverse effects. Patients should be advised to discontinue the medication and seek medical attention if they experience any unusual symptoms, especially visual disturbances or neurological effects.

Regulatory Status

Oxolamine’s regulatory status varies significantly across different regions worldwide. The medication is not approved by the Food and Drug Administration (FDA) in the United States, which limits its availability and clinical use in American medical practice. However, oxolamine has secured regulatory approval in numerous other countries and regions.

In New Zealand, oxolamine is classified as a prescription drug, requiring physician oversight for dispensing. Taiwan has specifically approved oxolamine for the treatment of respiratory tract inflammation. The medication is widely available in various countries including Mexico, Chile, Venezuela, Turkey, Peru, Paraguay, and Italy, among others.

The varying regulatory status reflects different approaches to evaluating the benefit-risk profile of oxolamine across regulatory authorities. This diversity in approval status highlights the importance of following local regulatory guidance when considering oxolamine for therapeutic use.

Pharmaceutical Formulations

Oxolamine is available in multiple pharmaceutical formulations to accommodate different patient needs and treatment scenarios. The most common formulation is syrup, which is particularly well-suited for pediatric patients and adults with difficulty swallowing tablets. Syrup concentrations vary, with common strengths including 1%, 1.4%, 10 mg/ml, 28 mg/5 ml, and 50 mg/5 ml.

Tablet formulations are also available for adult patients who prefer solid oral dosage forms. Additionally, suppository forms of oxolamine exist, typically at higher concentrations such as 500 mg, providing an alternative route of administration for patients unable to take oral medications.

A Chinese patent describes a specific method for preparing oxolamine syrup that involves creating a simple sugar syrup base by dissolving sucrose in boiled water, then mixing this with an aqueous solution of oxolamine and adding citric acid, methyl p-hydroxybenzoate, gardenia yellow, and orange essence. This formulation is designed to optimize taste, stability, and patient acceptability, particularly for pediatric populations.

Conclusion

Oxolamine represents a valuable therapeutic option for managing cough and respiratory tract inflammation in countries where it has received regulatory approval. Its dual mechanism as both an antitussive and anti-inflammatory agent provides effective symptomatic relief for conditions ranging from pharyngitis and bronchitis to pertussis. While generally well-tolerated with low toxicity, important considerations include its interaction with warfarin, limited use duration in pediatric patients, and varying regulatory status across different regions.

The medication’s availability in multiple formulations including syrups, tablets, and suppositories enhances its clinical utility across diverse patient populations. Nevertheless, the limited availability of comprehensive pharmacokinetic data and extensive clinical trials highlights the need for continued research to fully elucidate oxolamine’s therapeutic profile. Healthcare providers should remain vigilant about potential adverse effects and drug interactions while leveraging oxolamine’s benefits for appropriate patients suffering from respiratory conditions.